Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
16.25
+0.25 (+1.56%)
Official Closing Price
Updated: 7:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
Next >
Teva Launches New “Pivot to Growth” Strategy
May 18, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
May 15, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
May 10, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
May 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
May 03, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
April 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Launch New Growth Strategy at Investor Day
April 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
April 14, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Complete Response Letter Received for AVT02 Biologics License Application
April 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
April 11, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
March 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
March 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
March 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
March 09, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Teva to Present at the Barclays Global Healthcare Conference
March 07, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
March 01, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
February 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
February 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
February 24, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
February 23, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
February 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
February 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
February 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
January 19, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
January 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States
January 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.